{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Redhill Biopharma Ltd."},"Symbol":{"label":"Symbol","value":"RDHL"},"Address":{"label":"Address","value":"21 HA'ARBA'A STREET, TEL AVIV, 6473921, Israel"},"Phone":{"label":"Phone","value":"+972 35413131"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.redhillbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dror Ben-Asher","title":"Chairman & Chief Executive Officer"},{"name":"Gilead Raday","title":"Chief Operating Officer"},{"name":"Ira N. Kalfus","title":"Medical Director"},{"name":"Mark L. Levitt","title":"Chief Scientific Officer"},{"name":"Reza Fathi","title":"Senior Vice President-Research & Development"},{"name":"Terry F. Plasse","title":"Medical Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}